Breuer R I, Soergel K H, Lashner B A, Christ M L, Hanauer S B, Vanagunas A, Harig J M, Keshavarzian A, Robinson M, Sellin J H, Weinberg D, Vidican D E, Flemal K L, Rademaker A W
Evanston Hospital, Division of Gastroenterology, Evanston, Illinois 60201, USA.
Gut. 1997 Apr;40(4):485-91. doi: 10.1136/gut.40.4.485.
Short chain fatty acid (SCFA) deficiency is associated with colitis in animals and humans, and the mucosal metabolism of these compounds is decreased in ulcerative colitis.
To assess the efficacy of topical SCFA treatment in ulcerative colitis.
103 patients with distal ulcerative colitis were entered into a six week, double-blind, placebo controlled trial of rectal SCFA twice daily; patients who were unchanged on placebo were offered SCFA in an open-label extension trial.
Of the 91 patients completing the trial, more patients in the SCFA treated than in the placebo treated group improved (33% v 20%, p = 0.14, NS). Those on SCFA also had larger, but statistically non-significant, reductions in every component of their clinical and histological activity scores. In patients with a relatively short current episode of colitis (< 6 months, n = 42), more responded to SCFA than to placebo (48% v 18%, p = 0.03). These patients also had larger, but statistically non-significant, decreases in their clinical activity index (p = 0.08 v placebo). Every patient who improved used at least five of six of the prescribed rectal SCFA irrigations, whereas only 37% who did not improve were as compliant. In the open-label extension trial, 65% improved on SCFA; these patients also had significant reductions (p < 0.02) in their clinical and histological activity scores.
Although SCFA enemas were not of therapeutic value in this controlled trial, the results suggest efficacy in subsets of patients with distal ulcerative colitis including those with short active episodes. Prolonged contact with rectal mucosa seems to be necessary for therapeutic benefit.
短链脂肪酸(SCFA)缺乏与动物和人类的结肠炎相关,且这些化合物的黏膜代谢在溃疡性结肠炎中降低。
评估局部应用SCFA治疗溃疡性结肠炎的疗效。
103例远端溃疡性结肠炎患者进入一项为期六周的双盲、安慰剂对照试验,每日两次直肠给予SCFA;在安慰剂治疗无改善的患者进入开放标签延长试验接受SCFA治疗。
在完成试验的91例患者中,接受SCFA治疗组比安慰剂治疗组改善的患者更多(33%对20%,p = 0.14,无统计学意义)。接受SCFA治疗的患者其临床和组织学活动评分的各项指标降低幅度更大,但无统计学意义。在当前结肠炎发作相对较短(<6个月,n = 42)的患者中,对SCFA有反应的患者比安慰剂更多(48%对18%,p = 0.03)。这些患者的临床活动指数降低幅度也更大,但无统计学意义(与安慰剂相比p = 0.08)。每例病情改善的患者至少接受了规定的六次直肠SCFA灌肠中的五次,而病情未改善的患者中只有37%如此依从。在开放标签延长试验中,65%的患者在接受SCFA治疗后病情改善;这些患者的临床和组织学活动评分也显著降低(p < 0.02)。
尽管在该对照试验中SCFA灌肠无治疗价值,但结果提示对包括发作期短的患者在内的远端溃疡性结肠炎亚组患者有效。似乎需要与直肠黏膜长时间接触才能获得治疗益处。